1. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Juba, South Sudan: a population-based study
- Author
-
Rachel Mills, Jason B. Harris, Justin Lessler, John Hassen J, Lul Deng, Nyimol Mawien P, Joseph F. Wamala, Bior Bk, Damien Slater, Lino Loro Lako R, Forrest K. Jones, Richelle C. Charles, Baya Sk, Clare Fraser, Demby Mn, John Rumunu, Baguma A, Andrew S. Azman, Sylvester Maleghemi, Caflish A, Sanchez, Kirsten E. Wiens, Amanaya Iboyi J, Serina Moheed, Guracha Guyo A, and Oluseun Olu O
- Subjects
Veterinary medicine ,Coronavirus disease 2019 (COVID-19) ,serosurvey ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Juba ,Population ,Antibodies, Viral ,Article ,Serology ,Seroepidemiologic Studies ,antibodies ,Humans ,Medicine ,Seroprevalence ,education ,South Sudan ,Africa South of the Sahara ,education.field_of_study ,seroprevalence ,biology ,SARS-CoV-2 ,business.industry ,Transmission (medicine) ,COVID-19 ,serological survey ,Titer ,Cross-Sectional Studies ,Massachusetts ,Immunoglobulin G ,biology.protein ,Antibody ,business ,Boston - Abstract
BackgroundRelatively few COVID-19 cases and deaths have been reported through much of sub-Saharan Africa, including South Sudan, although the extent of SARS-CoV-2 spread remains unclear due to weak surveillance systems and few population-representative serosurveys.MethodsWe conducted a representative household-based cross-sectional serosurvey in Juba, South Sudan. We quantified IgG antibody responses to SARS-CoV-2 spike protein receptor-binding domain and estimated seroprevalence using a Bayesian regression model accounting for test performance.ResultsWe recruited 2,214 participants from August 10 to September 11, 2020 and 22.3% had anti-SARS-CoV-2 IgG titers above levels in pre-pandemic samples. After accounting for waning antibody levels, age, and sex, we estimated that 38.5% (32.1 - 46.8) of the population had been infected with SARS-CoV-2. For each RT-PCR confirmed COVID-19 case, 104 (87-126) infections were unreported. Background antibody reactivity was higher in pre-pandemic samples from Juba compared to Boston, where the serological test was validated. The estimated proportion of the population infected ranged from 30.1% to 60.6% depending on assumptions about test performance and prevalence of clinically severe infections.ConclusionsSARS-CoV-2 has spread extensively within Juba. Validation of serological tests in sub-Saharan African populations is critical to improve our ability to use serosurveillance to understand and mitigate transmission.
- Published
- 2021